Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients

Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher's exact test, and unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA) analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitts, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p=0.04). Lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population.


Introduction 66
Patients with hematologic malignancies have poor outcomes from COVID infection with associated mortality of up 67 to 30-40%. Studies have shown that these patients are less likely to mount an antibody response after COVID 68 infection [1]. The Pfizer-BioNTech and Moderna COVID mRNA vaccines have been shown to be 94% effective in preventing severe disease in the general population [2]. However, it is well known that certain clinically vulnerable 70 populations do not develop protective immunity after completing the COVID vaccine series [3].

72
Production of antibodies against the SARS-CoV-2 spike protein is the major mechanism of protective immunity 73 induced by COVID vaccination. Patients with lymphoma may be unable to seroconvert following vaccination due to 74 impaired humoral and T-cell immunity secondary to the malignancy itself as well as immunosuppressive treatment 75 [4]. This inability to produce antibodies against the SARS-CoV-2 spike protein is most notable in patients with B-cell 76 lymphomas and chronic lymphocytic leukemia (CLL), with seroconversion rates ranging between 64% to 78% [5].

77
Treatment with B-cell directed therapies, such as anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase 78 (BTK) inhibitors, further compromises the ability of patients with lymphoma to mount an antibody response 79 following vaccination and persists over time [6]. Vaccine responses in patients with different lymphoma subtypes 80 or receiving B-cell depleting therapies have not been fully elucidated.

82
With the emergence of the omicron variant and availability of an additional primary shot of the COVID vaccine, it 83 has become increasingly important to describe the efficacy of the COVID vaccines in lymphoma patients and to 84 suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. There 85 have been several reports of patients with lymphoma frequently not achieving serologic response to COVID 86 vaccines, especially after recent treatments with B-cell directed therapies [6,7]. In this study, we evaluated 87 antibody levels against the SARS-CoV-2 spike protein in lymphoma patients following receipt of the primary COVID 88 vaccination series and additional primary shot. We hypothesized that patients with lymphoma are not developing 89 a robust immune response following vaccination.

90
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Patient demographics and comorbidities
156 Two-hundred forty-three patients were identified with baseline characteristics as shown in Table 1. Overall, the 157 study population was elderly at a median age of 67 (IQR 59-75) years old, 52% of patients were male, and 78% of 158 patients were white. The most frequent comorbidities were cardiovascular disease (44%) and former smoking 159 history (30%). Lymphoma subtypes in our cohort were: indolent lymphomas (30%), Burkitt's, DLBCL, PMBL  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272883 doi: medRxiv preprint patients received COVID mRNA vaccines, and we were able to confirm the specific type in 197 (81%) patients. Only

Primary outcome
primary COVID vaccination series (Fig 1 and Table 2). There were 112 patients who received an additional primary 172 shot, but only 46 of these patients had anti-COVID spike antibody protein levels resulted at the time of data cut-173 off. Of these 46 patients, 38 patients (83%) had anti-COVID spike protein antibodies after receiving this dose (Table   174 2). Among the 38 patients who were seropositive after the additional primary dose, 18 patients were seronegative   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. There were 8 patients that were seronegative following the additional primary shot. Of these 8 patients, there was 185 1 patient that was seropositive after the primary series but was seronegative after the additional primary shot.

186
There were 7 patients that did not produce antibodies following both the primary vaccination series and additional  (Table 2). This rate was numerically lower than 85% (46/54) of those who developed antibodies and received . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

200
There were differences observed in the ability to produce serology with the COVID vaccine amongst lymphoma 201 subtypes. Of 55 patients with CLL/SLL, 28 (51%) produced antibodies after the primary COVID vaccination series 202 (Table 2 and Fig 2). There were 12 patients who received an additional primary shot, of which 92% were 203 seropositive (Fig 3). There were 20 CLL/SLL patients receiving anticancer treatment at the time of vaccination, of 204 which 7 (7/20, 35%) patients were seropositive after the primary series and 6 (6/7, 86%) after the additional 205 primary shot (Table 3)     is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272883 doi: medRxiv preprint (Table 2). There were 2 patients who received convalescent plasma, 4 patients who received monoclonal antibody therapy, and 1 patient who received both convalescent plasma and monoclonal antibody treatment for COVID 233 treatment.

236
In this retrospective, single center study, lymphoma patients (65%) were capable of mounting a humoral response

248
Approximately half (51%) of patients with CLL/SLL produced antibodies following their COVID vaccine, which was 249 considerably lower when compared to most subtypes of lymphoma. In contrast, patients with HL/TCL have been 250 shown to produce antibodies at higher rates 85%-98%, and this may be attributed to differences in disease biology

265
For patients receiving B-cell directed therapies, peripheral blood B-cell counts may begin to recover after 3 months 266 following treatment and may be completely reversed by 9 to 12 months [6]. A meta-analysis of thirty-eight studies 267 in patients treated with anti-CD20 monoclonal antibody therapy demonstrated that patients actively on these 268 therapies may have suboptimal antibody responses to all types of vaccines. This phenomenon was determined to 269 be at least partially ameliorated by 3-6 months following treatment, with repopulation of the B-cell pool in 12 270 months after treatment [8,9]. Similarly, patients in this study who received rituximab in the previous 12 months 271 had numerically lower seropositivity rates to the COVID vaccine compared to patients who had received rituximab 272 more than 12 months prior to vaccination. Of note, the majority of patients with Burkitt's, DLBCL or PMBL in this 273 study were not actively receiving anticancer therapy in the months prior to COVID vaccination and 75% were able 274 to mount a humoral response to vaccination. This suggests the ability of these patients to recover B-cell counts 275 following B-cell directed therapies and the need for optimal timing of vaccination following these therapies.

276
Furthermore, this adds to the complexity of predicting response to vaccines in patients with lymphoma. Not only is 277 it affected by the biology of the disease itself, but also the type of therapy they are receiving as well as its timing.

279
There are some limitations to this study. Firstly, this was a single-center, retrospective chart review. Some patients 280 received their COVID vaccine at an outside facility, therefore, the exact date and the type of vaccine received was 281 not consistently available. Secondly, the timing of the additional primary shot of COVID vaccine was not uniform 282 among all patients, and not all patients received this additional dose. As the COVID-19 pandemic progressed and 283 the Center for Disease Control updated recommendations based on available evidence, some patients received the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272883 doi: medRxiv preprint additional primary shot of the COVID vaccine closer to the recommended 28 days after completion of the primary 285 series than others, and some have yet to receive their additional primary shot. Lastly, although there were 243 286 patients evaluated in the overall analysis, some subgroups of particular interest had smaller numbers of patients.

288
In conclusion, lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines.

289
Although seroconversion is lower than in the normal population, it is still significant and warrants administration of 290 COVID vaccine without delay, particularly during continuing high rate of infection. CLL/SLL appears predictive of a 291 negative antibody response to the COVID vaccine, while HL/TCL histologies appeared to correlate to a positive 292 antibody response, even with treatment within 6 months of vaccination. Our study suggests anti-CD20 monoclonal 293 antibody therapy in the last 12 months may affect the ability to produce serology towards a COVID vaccine.

294
Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical 295 relevance in this patient population.

300
Data Availability: The study involves a review of the electronic medical records of lymphoma patients who 301 received the COVID vaccine. The research data set has removed most, but not all protected health information (for 302 example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The 303 dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore, 304 for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2022. ; https://doi.org/10.1101/2022.03.24.22272883 doi: medRxiv preprint